Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

Completed · Phase 2

Conditions studied: Anemia, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms

In brief

RATIONALE: Thalidomide may stop or slow the growth of cancer cells. Epoetin alfa may stimulate red blood cell production. Combining thalidomide with epoetin alfa may improve anemia, decrease the need for blood transfusions, and improve the quality of life in patients with myelodysplastic syndrome. PURPOSE: Phase II trial to study the effectiveness of combining thalidomide with epoetin alfa in treating anemia in patients who have myelodysplastic syndrome.

Key facts

Study ID

NCT00053001

Run by

Fallon Clinic

Starts

2001-06-01

Expected to finish

2007-10-01

Last updated by the study team

2013-06-26

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Fallon Clinic at Worcester Medical Center — Worcester, Massachusetts, United States
• UMASS Memorial Cancer Center - University Campus — Worcester, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.